Atezolizumab/bevacizumab for the management of HCC in 1st setting – Arndt Vogel
š„ off the press: Atezolizumab/bevacizumab for the management of HCC in 1st setting: systematic literature review & meta-analysis Gastroenterology,Karger Liver cancer.
š Individual comparisons suggest improved PFS/OS with Atezo/Bev vs most, but not all comparators.
For the article: Click here
Source: Arndt Vogel / Twitter
Arndt Vogel is a managing senior consultant and professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. He is the Head of the GI-Cancer Center and of the Center for Personalized Medicine at Medical School Hannover and chairs the Hepatobiliary Cancer Study Group of the AIO, a collaborative group in clinical oncology in Germany. His scientific focus is translational and clinical research in gastrointestinal cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023